Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Mostrar otras versiones (1)

BACKGROUND: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalgleish, Angus G, Stebbing, Justin, Adamson, Douglas JA, Arif, Seema Safia, Bidoli, Paolo, Chang, David, Cheeseman, Sue, Diaz-Beveridge, Robert, Fernandez-Martos, Carlos, Glynne-Jones, Rob, Granetto, Cristina, Massuti, Bartomeu, McAdam, Karen, McDermott, Raymond, Martín, Andrés J Muñoz, Papamichael, Demetris, Pazo-Cid, Roberto, Vieitez, Jose M, Zaniboni, Alberto, Carroll, Kevin J, Wagle, Shama, Gaya, Andrew, Mudan, Satvinder S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046215/
https://www.ncbi.nlm.nih.gov/pubmed/27599039
http://dx.doi.org/10.1038/bjc.2016.271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046215/
https://www.ncbi.nlm.nih.gov/pubmed/27599039
http://dx.doi.org/10.1038/bjc.2016.271

Ejemplares similares